Nav: Home

Case Western Reserve School of Nursing scientist to lead new cystic fibrosis research

December 17, 2015

CLEVELAND--A scientist at Case Western Reserve University Frances Payne Bolton School of Nursing will lead a pair of studies to develop more effective treatment for symptoms of cystic fibrosis (CF), a life-threatening genetic disease that causes persistent lung infections and progressively limits the ability to breathe.

About 30,000 people in the United States (70,000 worldwide) suffer from CF, with about 1,000 new cases diagnosed annually. Most CF patients are diagnosed as newborns.

A defective gene causes a thick buildup of mucus in the lungs, pancreas and other organs of CF patients. In the lungs, the mucus clogs airways, leading to extensive damage and, eventually, respiratory failure.

CF can be treated, but there is no cure. The average lifespan is less than 40 years.

Rebecca Darrah, assistant professor at the School of Nursing and assistant director of Case Western Reserve's Genetic Counseling Training Program, will direct two new studies to learn more about how gene-modifying treatment can be used to minimize the symptoms of CF.

Both research projects will begin in January.

"With these new studies," Darrah said, "we are hoping to not only develop new treatment strategies that would benefit all CF patients, but also determine the ideal timing for other clinical interventions already in place to help patients with specific mutations."

First study

Data from a recent genetic survey of CF patients suggest they may benefit from medications-- such as ACE inhibitors--that regulate blood pressure and fluid balance.

Scientists have found that worsening lung symptoms in CF patients are linked to variations in the genetic code for a receptor in a pathway related to high blood pressure (known as angiotensin) that restricts vessels and raises blood pressure. The researchers will try to determine if CF lung symptoms can be somewhat reduced by altering a specific component of the angiotensin pathway.

With funding from the Gilead Sciences Inc., Darrah and her team will study the effects of altering the angiotensin pathway in genetically modified mouse models. They will also determine whether giving CF mouse models medication designed to alter angiotensin signaling will have a positive effect on their breathing.

Darrah has already begun to analyze clinical data to determine if CF patients prescribed hypertensive drugs experienced improvement in lung symptoms. Since FDA-approved drugs targeting the angiotensin pathway exist, results could lead to a clinical trial in CF patients.

Second study

"Treating chronic diseases, such as CF, can be clinically challenging because it is often unclear whether disease symptoms can be reversed or whether the best hope is just to slow the progression of the disease," Darrah said. "With clinical trials of new drugs to correct the genetic defect that causes CF, knowing the ideal timing of this treatment is critical."

In the second study, with a grant from the Cystic Fibrosis Foundation, mouse models of CF will undergo genetic "correction" of the mutations causing the disease when exposed to a certain drug.

In this study, researchers hope to:
  • Determine which of the respiratory symptoms are reversible or preventable with genetic correction.

  • Determine the ideal timing of genetic correction. Would treatment be most effective as infants to prevent lung disease or can it also be given to adults to reverse lung disease?

  • Determine the amount of genetic correction required. Does the gene have to be corrected completely or would partial correction help alleviate or prevent symptoms?

The findings are expected to help design more effective clinical trials by providing important data on CF lung symptoms that are correctable and reversible, and the timing necessary to achieve these clinical benefits.
-end-
Case Western Reserve University is one of the country's leading private research institutions. Located in Cleveland, we offer a unique combination of forward-thinking educational opportunities in an inspiring cultural setting. Our leading-edge faculty engage in teaching and research in a collaborative, hands-on environment. Our nationally recognized programs include arts and sciences, dental medicine, engineering, law, management, medicine, nursing and social work. About 4,900 undergraduate and 5,900 graduate students comprise our student body. Visit case.edu to see how Case Western Reserve thinks beyond the possible.

Case Western Reserve University

Related Cystic Fibrosis Articles:

Cystic fibrosis alters the structure of mucus in airways
Cystic fibrosis (CF) alters the structure of mucus produced in airway passages.
Cystic fibrosis study offers new understanding of silent changes in genes
Researchers studying the root cause of cystic fibrosis have made a major advance in our understanding of silent gene changes with implications for the complexity of cystic fibrosis.
New imaging technique shows effectiveness of cystic fibrosis drug
Cystic fibrosis currently has no cure, though a drug approved by the Food and Drug Administration treats the underlying cause of the disease.
New study resolves the structure of the human protein that causes cystic fibrosis
In order to better understand how genetic mutations give rise to cystic fibrosis, researchers need to map the protein responsible for the disorder.
New molecules identified that could help in the fight to prevent cystic fibrosis
New research has identified new molecules that could help in the fight to prevent diseases caused by faulty ion channels, such as cystic fibrosis.
Newborn screening for cystic fibrosis
A new study led by a team from the Research Institute of the McGill University Health Centre and Cystic Fibrosis Canada reinforces the benefits of newborn screening for cystic fibrosis (CF) patients.
Evolving insights into cystic fibrosis lung infections
Recent research progress into how bacteria adapt and evolve during chronic lung infections in cystic fibrosis patients could lead to better treatment strategies being developed, according to a new review by the University of Liverpool.
Key hurdle overcome in the development of a drug against cystic fibrosis
In people suffering from cystic fibrosis the CFTR protein is not located in the right place in mucus-producing cells: it remains inside the cell while it should be in the cell wall.
Researchers further illuminate pathway for treatment of cystic fibrosis
By studying alveolar macrophages, which provide our airways with a crucial defense against pathogens, UNC scientists are now able to more fully understand the larger picture of CF symptoms and continue progress towards targeted treatments, aside from addressing the mutated CFTR gene.
Gene therapy: A promising candidate for cystic fibrosis treatment
An improved gene therapy treatment can cure mice with cystic fibrosis (CF).

Related Cystic Fibrosis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...